Eli Lilly & Co (LLY) Stock Forecast & Price Target

Compare

20,571 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

19 Buy

2 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$1,174.17

▲(12.74% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $1,174.17 with a high forecast of $1,500.00 and a low forecast of $950.00. The average price target represents a 12.74% change from the last price of $1,041.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"733":"$733","925":"$925","1117":"$1,117","1309":"$1,309","1501":"$1,501"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1174.1666666666665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":950,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$950.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[733,925,1117,1309,1501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1074.68,1107.396923076923,1140.1138461538462,1172.8307692307692,1205.5476923076924,1238.2646153846154,1270.9815384615385,1303.6984615384615,1336.4153846153847,1369.1323076923077,1401.8492307692309,1434.5661538461538,1467.2830769230768,{"y":1500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1074.68,1082.3328205128205,1089.9856410256411,1097.6384615384616,1105.291282051282,1112.9441025641026,1120.596923076923,1128.2497435897435,1135.902564102564,1143.5553846153846,1151.208205128205,1158.8610256410254,1166.513846153846,{"y":1174.1666666666665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1074.68,1065.0892307692309,1055.4984615384617,1045.9076923076923,1036.316923076923,1026.726153846154,1017.1353846153846,1007.5446153846154,997.9538461538461,988.363076923077,978.7723076923077,969.1815384615385,959.5907692307692,{"y":950,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":766.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":805.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":915.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":800.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":789.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":744.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":773.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":759.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":734.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":824.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":861.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1057.89,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1074.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,500

Average Price Target$1,174

Lowest Price Target$950.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Risinger

Leerink Partners

Buy

―

Reiterated

01/08/26

Eli Lilly’s Ventyx Acquisition: Expanding Inflammation and Inflammaging Pipeline to Strengthen Long‑Term Growth and Support Buy RatingWe view LLY’s January 7 announcement of plans to acquire Ventyx Biosciences (VTYX, not rated) for $1.2B positively, given the potential for Ventyx’s R&D portfolio to address large inflammatory disease markets. The potential for drug treatments to help address “inflammaging” offers huge potential, in our view. We would highlight a Endocrinology article “Inflammaging: a new immune–metabolic viewpoint for age-related diseases” (Franceschi et al. 2026 Nature Reviews Endocrinology). VTYX is developing NLRP3 inhibitors for a range of inflammatory diseases and delivered compelling proof-of-concept results in Oct ’25 (PR here) when VTX3232 demonstrated significantly reduced biological markets of inflammation.

Michael Yee

UBS

$1,080→$1,250

Buy

20.02%

Upside

Reiterated

01/07/26

Eli Lilly & Co (LLY) Receives a New Rating from Jefferies

Kerry Holford

Berenberg Bank

$950

Hold

-8.79%

Downside

Reiterated

01/06/26

Analysts Are Neutral on Top Healthcare Stocks: Merck & Company (MRK), Eli Lilly & Co (LLY)

Geoff Meacham

Citi

$1,500

Buy

44.02%

Upside

Reiterated

01/05/26

Citi Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Nico Chen

DBS

$1,333

Buy

27.99%

Upside

Reiterated

01/02/26

Analysts Are Bullish on Top Healthcare Stocks: IDEAYA Biosciences (IDYA), Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

$1,300

Buy

24.82%

Upside

Reiterated

12/26/25

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), BioLife Solutions (NASDAQ: BLFS) and Eli Lilly & Co (NYSE: LLY)

Jason Gerberry

Bank of America Securities

$1,268

Buy

21.75%

Upside

Reiterated

12/18/25

Eli Lilly: Reinforcing Obesity Market Leadership With Orforglipron and a Diversified Growth Pipeline

Evan Seigerman

BMO Capital

$1,200

Buy

15.22%

Upside

Reiterated

12/17/25

BMO Capital Remains a Buy on Eli Lilly & Co (LLY)

Narumi Nakagiri

Daiwa

$1,230

Buy

18.10%

Upside

Upgraded

12/16/25

Eli Lilly upgraded to Buy from Neutral at DaiwaEli Lilly upgraded to Buy from Neutral at Daiwa

Asad Haider

Goldman Sachs

$951→$1,145

Buy

9.94%

Upside

Reiterated

12/15/25

Eli Lilly price target raised to $1,145 from $951 at Goldman SachsEli Lilly price target raised to $1,145 from $951 at Goldman Sachs

Srikripa Devarakonda

Truist Financial

Buy

―

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Evommune, Inc. (NYSE: EVMN) and Eli Lilly & Co (NYSE: LLY)

Louise Chen

Scotiabank

$1,165

Buy

11.86%

Upside

Reiterated

12/12/25

Eli Lilly & Co (LLY) Gets a Buy from Scotiabank

Terence Flynn

Morgan Stanley

$1,290

Buy

23.86%

Upside

Reiterated

12/11/25

Morgan Stanley sees 'minimal movement' in Eli Lilly shares on retatrutide dataMorgan Stanley sees 'minimal movement' in Eli Lilly shares on retatrutide data

Mohit Bansal

Wells Fargo

$1,100→$1,200

Buy

15.22%

Upside

Reiterated

12/10/25

Wells Fargo Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Rajesh Kumar

HSBC

$850→$1,070

Hold

2.74%

Upside

Reiterated

12/10/25

Eli Lilly price target raised to $1,070 from $850 at HSBCEli Lilly price target raised to $1,070 from $850 at HSBC

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Risinger

Leerink Partners

Buy

―

Reiterated

01/08/26

Michael Yee

UBS

$1,080→$1,250

Buy

20.02%

Upside

Reiterated

01/07/26

Eli Lilly & Co (LLY) Receives a New Rating from Jefferies

Kerry Holford

Berenberg Bank

$950

Hold

-8.79%

Downside

Reiterated

01/06/26

Analysts Are Neutral on Top Healthcare Stocks: Merck & Company (MRK), Eli Lilly & Co (LLY)

Geoff Meacham

Citi

$1,500

Buy

44.02%

Upside

Reiterated

01/05/26

Citi Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Nico Chen

DBS

$1,333

Buy

27.99%

Upside

Reiterated

01/02/26

Analysts Are Bullish on Top Healthcare Stocks: IDEAYA Biosciences (IDYA), Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

$1,300

Buy

24.82%

Upside

Reiterated

12/26/25

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), BioLife Solutions (NASDAQ: BLFS) and Eli Lilly & Co (NYSE: LLY)

Jason Gerberry

Bank of America Securities

$1,268

Buy

21.75%

Upside

Reiterated

12/18/25

Eli Lilly: Reinforcing Obesity Market Leadership With Orforglipron and a Diversified Growth Pipeline

Evan Seigerman

BMO Capital

$1,200

Buy

15.22%

Upside

Reiterated

12/17/25

BMO Capital Remains a Buy on Eli Lilly & Co (LLY)

Narumi Nakagiri

Daiwa

$1,230

Buy

18.10%

Upside

Upgraded

12/16/25

Eli Lilly upgraded to Buy from Neutral at DaiwaEli Lilly upgraded to Buy from Neutral at Daiwa

Asad Haider

Goldman Sachs

$951→$1,145

Buy

9.94%

Upside

Reiterated

12/15/25

Eli Lilly price target raised to $1,145 from $951 at Goldman SachsEli Lilly price target raised to $1,145 from $951 at Goldman Sachs

Srikripa Devarakonda

Truist Financial

Buy

―

Reiterated

12/12/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Evommune, Inc. (NYSE: EVMN) and Eli Lilly & Co (NYSE: LLY)

Louise Chen

Scotiabank

$1,165

Buy

11.86%

Upside

Reiterated

12/12/25

Eli Lilly & Co (LLY) Gets a Buy from Scotiabank

Terence Flynn

Morgan Stanley

$1,290

Buy

23.86%

Upside

Reiterated

12/11/25

Morgan Stanley sees 'minimal movement' in Eli Lilly shares on retatrutide dataMorgan Stanley sees 'minimal movement' in Eli Lilly shares on retatrutide data

Mohit Bansal

Wells Fargo

$1,100→$1,200

Buy

15.22%

Upside

Reiterated

12/10/25

Wells Fargo Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Rajesh Kumar

HSBC

$850→$1,070

Hold

2.74%

Upside

Reiterated

12/10/25

Eli Lilly price target raised to $1,070 from $850 at HSBCEli Lilly price target raised to $1,070 from $850 at HSBC

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

1 Month

xxx

Success Rate

34/45 ratings generated profit

Average Return

+5.10%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.56% of your transactions generating a profit, with an average return of +5.10% per trade.

3 Months

xxx

Success Rate

34/44 ratings generated profit

Average Return

+12.79%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.27% of your transactions generating a profit, with an average return of +12.79% per trade.

1 Year

Geoff MeachamCiti

Success Rate

43/44 ratings generated profit

Average Return

+43.57%

reiterated a buy rating 4 days ago

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.73% of your transactions generating a profit, with an average return of +43.57% per trade.

2 Years

xxx

Success Rate

35/35 ratings generated profit

Average Return

+84.29%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +84.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 44 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,174.17.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $7.22 with a range of $6.66 to $8.72. The previous quarter’s EPS was $7.02. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $17.86B with a range of $17.11B to $19.24B. The previous quarter’s sales results were $17.60B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly And Company’s 12-month average price target is 1,174.17.

What is LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly And Company has 12.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LLY a Buy, Sell or Hold?

Eli Lilly And Company has a consensus rating of Strong Buy which is based on 19 buy ratings, 2 hold ratings and 0 sell ratings.

What is Eli Lilly And Company’s price target?

The average price target for Eli Lilly And Company is 1,174.17. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,500.00 ,the lowest forecast is $950.00. The average price target represents 12.74% Increase from the current price of $1,041.51.

What do analysts say about Eli Lilly And Company?

Eli Lilly And Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of LLY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts